Marea Therapeutics doses first patient in MAR002 phase 2 trial
AI Summary
Marea Therapeutics has dosed the first patient in its MAR002 Phase 2 trial. The update marks the beginning of patient treatment in the company's mid-stage clinical study.
Marea Therapeutics has dosed the first patient in its MAR002 Phase 2 trial. The update marks the beginning of patient treatment in the company's mid-stage clinical study.
Punch Nigeria —
Channel NewsAsia —
GDACS Alerts —
GDACS Alerts —
Wired —
GDACS Alerts —